4.68
-0.19 (-3.90%)
| Previous Close | 4.87 |
| Open | 4.90 |
| Volume | 2,791,659 |
| Avg. Volume (3M) | 3,263,003 |
| Market Cap | 792,957,632 |
| Price / Earnings (TTM) | 15.60 |
| Price / Earnings (Forward) | 14.20 |
| Price / Sales | 5.07 |
| Price / Book | 7.50 |
| 52 Weeks Range | |
| Earnings Date | 16 Mar 2026 |
| Profit Margin | 28.19% |
| Operating Margin (TTM) | 44.43% |
| Diluted EPS (TTM) | 0.480 |
| Quarterly Revenue Growth (YOY) | 22.80% |
| Quarterly Earnings Growth (YOY) | 70.60% |
| Total Debt/Equity (MRQ) | 32.53% |
| Current Ratio (MRQ) | 1.73 |
| Operating Cash Flow (TTM) | -81.23 M |
| Levered Free Cash Flow (TTM) | -53.07 M |
| Return on Assets (TTM) | 15.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CytomX Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -1.25 |
|
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 47.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Financial Engines Advisors L.L.C. | 31 Dec 2025 | 3,828,717 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 10.00 (Guggenheim, 113.68%) | Buy |
| 10.00 (Cantor Fitzgerald, 113.68%) | Buy | |
| 10.00 (Barclays, 113.68%) | Buy | |
| 10.00 (Piper Sandler, 113.68%) | Buy | |
| Median | 10.00 (113.68%) | |
| Average | 10.00 (113.68%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 5.44 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 09 Mar 2026 | 10.00 (113.68%) | Buy | 5.03 |
| 20 Jan 2026 | 10.00 (113.68%) | Buy | 5.37 | |
| Barclays | 04 Feb 2026 | 10.00 (113.68%) | Buy | 5.67 |
| 20 Jan 2026 | 8.00 (70.94%) | Buy | 5.37 | |
| Cantor Fitzgerald | 04 Feb 2026 | 10.00 (113.68%) | Buy | 5.67 |
| Piper Sandler | 20 Jan 2026 | 10.00 (113.68%) | Buy | 5.37 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | CytomX Therapeutics to Present at Upcoming February Conferences |
| 08 Jan 2026 | Announcement | CytomX Therapeutics Announces Business Update and Company Milestones for 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |